Latest News and Press Releases
Want to stay updated on the latest news?
-
Processa’s Phase 1b open label, multicenter trial is currently enrolling patients who have advanced, relapsed GI cancer that are refractory or intolerant to other therapies and are candidates for...
-
HANOVER, March 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical...
-
HANOVER, MD, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA) announced today that it has entered into a licensing agreement with Yuhan Corporation, a South Korean...